Sindilizumab currently has no indication for gastric cancer, but some patients can get better results with its use. Sindilizumab is commonly used to treat refractory or recurrent, classical Hodgkin’s lymphoma that has undergone at least second-line systemic chemotherapy. In combination with bevacizumab, it is used to treat unresectable or metastatic hepatocellular carcinoma that has not been previously treated systemically. And gemcitabine and platinum-based chemotherapy, can treat inoperable advanced or recurrent squamous cell non-small cell lung cancer. Clinical treatment of gastric cancer is mostly based on surgery, and early stage patients have the possibility of obtaining radical cure through surgery. According to the factors of severity, clinical staging and individual condition, patients in progressive stage can combine perioperative radiotherapy, chemotherapy and biotargeted therapy on the basis of surgery to prolong the survival time. Patients can follow the guidance of professional doctors to choose appropriate drugs. Drugs should be used under the guidance of doctors, do not blindly use drugs.